Project
Cruz HBR
Completed · 2020 until 2022
Schneider Irene, Fink Karin, Weilenmann Daniel
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2020
End Date
2022
Financing
Industry
Study Design
Prospective, multi-center, open-label, single-arm registry designed to
enroll 1200 (800 non-High Bleeding Risk (non-HBR) and 400 HBR) allcomer patients with coronary artery disease in around 25 sites in 3
European countries (Switzerland, Germany & France).
Patients will receive at least one Supraflex Cruz™ sirolimus-eluting stent as per current practice and will be followed up for 12 months.
Brief description/objective
Post-market registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease